<DOC>
	<DOCNO>NCT01693731</DOCNO>
	<brief_summary>The purpose study determine aromatase inhibitor ( AIs ) Arimidex , Aromasin Femara affect woman 's oral health oral health relate quality life . Patients , dental professional medical oncologist benefit great understand best oral care follow practice breast cancer survivor use aromatase inhibitor .</brief_summary>
	<brief_title>Oral Health Breast Cancer Survivors Aromatase Inhibitors</brief_title>
	<detailed_description>OBJECTIVES : Primary This cross-sectional prevalence study seek investigate incidence severity oral health change , specifically periodontal condition , among breast cancer survivor way outcomes affect quality life . Secondary - To determine prevalence severity oral condition postmenopausal woman early stage breast cancer use adjuvant AI therapy compare postmenopausal woman use adjuvant AI therapy . - To determine adjuvant AI therapy use associate great alveolar bone loss increase level bone turnover biomarkers postmenopausal woman cancer undergo adjuvant AI therapy compare postmenopausal woman receive AI therapy . - To determine oral health-related quality life among postmenopausal woman early stage breast cancer receive adjuvant AI therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Periodontal Diseases</mesh_term>
	<mesh_term>Gingival Diseases</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Postmenopausal define NCCN ( follow ) Prior bilateral oophorectomy Age equal great 60 year age Age le 60 amenorrheic 12 month absence chemotherapy , tamoxifen , toremifen ovarian suppression FSH estradiol postmenopausal range If take tamoxifen toremifen age less 60y , FSH plasma estradiol level postmenopausal range Informed consent Individuals capable consent self administer survey instrument Dentate At least 15 teeth present . AI user : Diagnosis BCa Histologic confirm diagnosis BCa : Stage 0 , I , II , III evidence metastatic disease . Treatment AI clinically indicate ( AI may anastrozole , exemestane letrozole ) &gt; 1 month . Subjects may prior tamoxifen raloxifene . Subjects may chemotherapy and/or radiation therapy . Must within first year consecutive AI therapy . If subject start AI , discontinue , restart , accept study . Controls : No Diagnosis cancer . Patients must diagnosis cancer ( Not include history localize thyroid skin cancer ) . Medical history Metastatic BCa ( AI treat group : fully resect locally recurrent disease permit patient render without evidence disease ) . Significant psychiatric illness/social situation would preclude completion questionnaire . Medications Chronic medication know affect periodontal status ( calcium antagonist , anticonvulsives , immunosuppressive ( &gt; prednisone 7.5mg daily ) . NSAIDS bisphosphonates permit . Premedication Conditions require antibiotic therapy evaluate casebycase basis . ( Patients take prophylaxis joint replacement exclude . )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Periodontal Diseases</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>Oral Health Related Quality Life</keyword>
</DOC>